Zobrazeno 1 - 10
of 337
pro vyhledávání: '"Robert J, Fox"'
Autor:
Joshua K. Johnson, Aaron C. Hamilton, Bo Hu, Quinn R. Pack, Peter K. Lindenauer, Robert J. Fox, Ardeshir Hashmi, Lee Anne Siegmund, Christian N. Burchill, Glen B. Taksler, Toyomi Goto, Mary Stilphen, Michael B. Rothberg
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-14 (2023)
Abstract Background Hospitalized older adults spend as much as 95% of their time in bed, which can result in adverse events and delay recovery while increasing costs. Observational studies have shown that general mobility interventions (e.g., ambulat
Externí odkaz:
https://doaj.org/article/2466358fb9164a9caf330b534bafc236
Autor:
Jai Perumal, Roumen Balabanov, Laura Balcer, Steven Galetta, Zhaonan Sun, Hanyue Li, Danette Rutledge, Robin L. Avila, Robert J. Fox
Publikováno v:
Neurology and Therapy, Vol 12, Iss 3, Pp 833-848 (2023)
Abstract Introduction In STRIVE, natalizumab treatment demonstrated effectiveness in clinical, magnetic resonance imaging (MRI), and patient-reported outcomes (PROs) in patients with early relapsing–remitting multiple sclerosis (RRMS). This post ho
Externí odkaz:
https://doaj.org/article/5c821f4c41a3497980c7a8b0b691e1de
Autor:
Robert J. Fox, Heinz Wiendl, Christian Wolf, Nicola De Stefano, Johann Sellner, Viktoriia Gryb, Konrad Rejdak, Plamen Stoyanov Bozhinov, Nataliya Tomakh, Iryna Skrypchenko, Andreas R. Muehler
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 9, Iss 7, Pp 977-987 (2022)
Abstract Objective Inhibition of dihydroorotate dehydrogenase suppresses magnetic resonance imaging brain lesions and disease activity in multiple sclerosis but has limiting tolerability. We assessed the safety and efficacy of vidofludimus calcium, a
Externí odkaz:
https://doaj.org/article/20b5a8195d66471c8d36116775ea8d4f
Publikováno v:
BMC Neurology, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Over a dozen disease-modifying therapies (DMTs) have been approved for treatment of multiple sclerosis (MS). Treatment guidelines focus on when to initiate, change, and discontinue treatment but provide little guidance on how to s
Externí odkaz:
https://doaj.org/article/6d2492c464094791988411a8c1330d48
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
ObjectiveResearch directly examining brain tissue has played an important role in understanding the pathology and pathogenesis of multiple sclerosis (MS) and other diseases of the central nervous system. Such research relies heavily on donations of p
Externí odkaz:
https://doaj.org/article/48c0e294464e4127be15e8ac13c2a157
Publikováno v:
Research Ethics Review, Vol 19 (2023)
The ethical recruitment of participants with neurological disorders in clinical research requires obtaining initial and ongoing informed consent. The purpose of this study is to characterize barriers faced by research personnel in obtaining informed
Externí odkaz:
https://doaj.org/article/3c4f5aa0f3cb43008c38e6743c31e18d
Multiple Sclerosis and Related Disorders provides evidence-based data and experience-based guidance for delivering quality long-term care to MS patients. Information on disease history, pathophysiology, and biology is included to provide clinicians w
Publikováno v:
Frontiers in Neurology, Vol 12 (2021)
Objective: Since the properties of health-related quality of life measures vary across samples, studies directly comparing the properties of different measures can be useful in understanding their relative strengths and limitations. We aimed to compa
Externí odkaz:
https://doaj.org/article/b28bc879cf7443feb14c6708769bfd4c
Autor:
Amber Salter, Samantha Lancia, Gary Cutter, Ruth Ann Marrie, Jason P. Mendoza, James B. Lewin, Robert J. Fox
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Background: Although the aggregate of data among patients with multiple sclerosis (MS) have shown similar efficacy between dimethyl fumarate (DMF) and fingolimod (FTY), most studies have not assessed long-term worsening of disability. We compared lon
Externí odkaz:
https://doaj.org/article/e04de41d27284c029367f92f503324e1
Autor:
Jai Perumal, Robert J. Fox, Roumen Balabanov, Laura J. Balcer, Steven Galetta, Shavy Makh, Sourav Santra, Christophe Hotermans, Lily Lee
Publikováno v:
BMC Neurology, Vol 19, Iss 1, Pp 1-12 (2019)
Abstract Background STRIVE is a multicenter, observational, open-label, single-arm study of natalizumab in anti–JC virus (JCV) seronegative patients with early relapsing-remitting multiple sclerosis (RRMS). The objective of this prespecified 2-year
Externí odkaz:
https://doaj.org/article/0a6e2137e27b4e0ea304899ccd3fcf9a